Seeking Alpha
08 Dec 2025, 22:17 UTC · 49w ago
Kura Oncology, Inc. (KURA) Discusses Ziftomenib Combination Data in Newly Diagnosed and Relapsed/Refractory NPM1-m and KMT2A-r AML Transcript
Verdict
Headline takes no side. We score KURA +0.50 across one claim — strongly bullish.
- Expected · KURA
+0.50strongly bullish
−1 bearish0bullish +1More positive than 72% of ticker scores this week





